Skip to main navigation Skip to search Skip to main content

Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury

  • Annayya R. Aroor
  • , Nitin A. Das
  • , Andrea J. Carpenter
  • , Javad Habibi
  • , Guanghong Jia
  • , Francisco I. Ramirez-Perez
  • , Luis Martinez-Lemus
  • , Camila M. Manrique-Acevedo
  • , Melvin R. Hayden
  • , Cornel Duta
  • , Ravi Nistala
  • , Eric Mayoux
  • , Jaume Padilla
  • , Bysani Chandrasekar
  • , Vincent G. DeMarco

Research output: Contribution to journal › Article › peer-review

162   Link opens in a new tab Scopus citations

Fingerprint

Dive into the research topics of 'Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury'. Together they form a unique fingerprint.
Sort by

Medicine and Dentistry

Biochemistry, Genetics and Molecular Biology

Pharmacology, Toxicology and Pharmaceutical Science